Price
Target price
€79.16
€79.16
0.460%
0.36
0.460%
€105.83
17.07.26 / Tradegate
WKN: 529882 / Symbol: CORT / Name: Corcept / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corcept Therapeutics Inc. Stock
Corcept Therapeutics Inc. gained 0.460% compared to yesterday.
Corcept Therapeutics Inc. is currently one of the favorites of our community with 14 Buy predictions and no Sell predictions.
As a result the target price of 105 € shows a positive potential of 32.64% compared to the current price of 79.16 € for Corcept Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Corcept Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 0.460% | -1.665% | 11.336% | 25.571% | 15.765% | 288.039% | 357.572% |
| Pacira Pharmaceuticals | -0.900% | -0.901% | 12.245% | 15.183% | 1.852% | -33.735% | -52.174% |
| Supernus Pharmaceuticals | -0.480% | -1.415% | 10.582% | 47.183% | -2.791% | 60.769% | 90.000% |
| Collegium Pharmaceutical Inc | -1.270% | 1.299% | 6.849% | 16.418% | -24.638% | 64.211% | 56.784% |
Comments
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $110.00 to $135.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
News
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
William Guyer, chief development officer, reported a sale of 20,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 7, 2026, according to an SEC Form 4 filing.
Corcept
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its